vs
Side-by-side financial comparison of INTEGRA LIFESCIENCES HOLDINGS CORP (IART) and JACK IN THE BOX INC (JACK). Click either name above to swap in a different company.
INTEGRA LIFESCIENCES HOLDINGS CORP is the larger business by last-quarter revenue ($434.9M vs $349.5M, roughly 1.2× JACK IN THE BOX INC). On growth, INTEGRA LIFESCIENCES HOLDINGS CORP posted the faster year-over-year revenue change (-1.7% vs -25.5%). JACK IN THE BOX INC produced more free cash flow last quarter ($7.3M vs $-5.4M). Over the past eight quarters, INTEGRA LIFESCIENCES HOLDINGS CORP's revenue compounded faster (8.6% CAGR vs -18.6%).
Integra LifeSciences Holdings Corporation is a global medical device manufacturing company headquartered in Princeton, New Jersey. Founded in 1989, the company manufactures products for skin regeneration, neurosurgery, reconstructive and general surgery. Integra artificial skin became the first commercially reproducible skin tissue used to treat severe burns and other skin wounds.
Jack in the Box, Inc. is an American fast food restaurant chain founded on February 21, 1951, by Robert O. Peterson in San Diego, California, where it is headquartered. The chain has over 2,200 locations, primarily serving the West Coast of the United States. Restaurants are also found in large urban areas outside the West Coast, as well as two in Guam. The company also formerly operated the Qdoba Mexican Grill chain until Apollo Global Management bought the chain in December 2017.
IART vs JACK — Head-to-Head
Income Statement — Q4 FY2025 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $434.9M | $349.5M |
| Net Profit | — | $-2.5M |
| Gross Margin | 50.8% | — |
| Operating Margin | 5.3% | 13.3% |
| Net Margin | — | -0.7% |
| Revenue YoY | -1.7% | -25.5% |
| Net Profit YoY | — | -107.3% |
| EPS (diluted) | $-0.03 | $-0.13 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | — | $349.5M | ||
| Q4 25 | $434.9M | — | ||
| Q3 25 | $402.1M | — | ||
| Q2 25 | $415.6M | $336.7M | ||
| Q1 25 | $382.7M | $371.1M | ||
| Q4 24 | $442.6M | — | ||
| Q3 24 | $380.8M | — | ||
| Q2 24 | $418.2M | $365.3M |
| Q1 26 | — | $-2.5M | ||
| Q4 25 | — | — | ||
| Q3 25 | $-5.4M | — | ||
| Q2 25 | $-484.1M | $-142.2M | ||
| Q1 25 | $-25.3M | $33.7M | ||
| Q4 24 | — | — | ||
| Q3 24 | $-10.7M | — | ||
| Q2 24 | $-12.4M | $25.0M |
| Q1 26 | — | — | ||
| Q4 25 | 50.8% | — | ||
| Q3 25 | 51.5% | — | ||
| Q2 25 | 50.4% | — | ||
| Q1 25 | 50.8% | — | ||
| Q4 24 | 56.3% | — | ||
| Q3 24 | 52.6% | — | ||
| Q2 24 | 54.0% | — |
| Q1 26 | — | 13.3% | ||
| Q4 25 | 5.3% | — | ||
| Q3 25 | 2.9% | — | ||
| Q2 25 | -123.4% | -46.7% | ||
| Q1 25 | -4.0% | 19.0% | ||
| Q4 24 | 8.0% | — | ||
| Q3 24 | -2.1% | — | ||
| Q2 24 | -0.7% | 14.8% |
| Q1 26 | — | -0.7% | ||
| Q4 25 | — | — | ||
| Q3 25 | -1.3% | — | ||
| Q2 25 | -116.5% | -42.2% | ||
| Q1 25 | -6.6% | 9.1% | ||
| Q4 24 | — | — | ||
| Q3 24 | -2.8% | — | ||
| Q2 24 | -3.0% | 6.8% |
| Q1 26 | — | $-0.13 | ||
| Q4 25 | $-0.03 | — | ||
| Q3 25 | $-0.07 | — | ||
| Q2 25 | $-6.31 | $-7.47 | ||
| Q1 25 | $-0.33 | $1.75 | ||
| Q4 24 | $0.25 | — | ||
| Q3 24 | $-0.14 | — | ||
| Q2 24 | $-0.16 | $1.26 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $263.7M | — |
| Total DebtLower is stronger | $726.6M | $1.6B |
| Stockholders' EquityBook value | $1.0B | $-936.0M |
| Total Assets | $3.6B | $2.0B |
| Debt / EquityLower = less leverage | 0.70× | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $263.7M | — | ||
| Q3 25 | $267.9M | — | ||
| Q2 25 | $253.6M | — | ||
| Q1 25 | $273.3M | — | ||
| Q4 24 | $273.6M | — | ||
| Q3 24 | $277.6M | — | ||
| Q2 24 | $296.9M | — |
| Q1 26 | — | $1.6B | ||
| Q4 25 | $726.6M | — | ||
| Q3 25 | $736.3M | — | ||
| Q2 25 | $745.9M | $1.7B | ||
| Q1 25 | $755.6M | $1.7B | ||
| Q4 24 | $760.5M | — | ||
| Q3 24 | $765.3M | — | ||
| Q2 24 | $770.2M | $1.7B |
| Q1 26 | — | $-936.0M | ||
| Q4 25 | $1.0B | — | ||
| Q3 25 | $1.0B | — | ||
| Q2 25 | $1.0B | $-976.2M | ||
| Q1 25 | $1.5B | $-827.1M | ||
| Q4 24 | $1.5B | — | ||
| Q3 24 | $1.5B | — | ||
| Q2 24 | $1.5B | $-702.6M |
| Q1 26 | — | $2.0B | ||
| Q4 25 | $3.6B | — | ||
| Q3 25 | $3.6B | — | ||
| Q2 25 | $3.7B | $2.6B | ||
| Q1 25 | $4.1B | $2.8B | ||
| Q4 24 | $4.0B | — | ||
| Q3 24 | $4.1B | — | ||
| Q2 24 | $4.1B | $2.9B |
| Q1 26 | — | — | ||
| Q4 25 | 0.70× | — | ||
| Q3 25 | 0.71× | — | ||
| Q2 25 | 0.72× | — | ||
| Q1 25 | 0.50× | — | ||
| Q4 24 | 0.49× | — | ||
| Q3 24 | 0.50× | — | ||
| Q2 24 | 0.50× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $11.8M | $30.5M |
| Free Cash FlowOCF − Capex | $-5.4M | $7.3M |
| FCF MarginFCF / Revenue | -1.2% | 2.1% |
| Capex IntensityCapex / Revenue | 4.0% | 6.6% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $-31.1M | $34.8M |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | $30.5M | ||
| Q4 25 | $11.8M | — | ||
| Q3 25 | $40.9M | — | ||
| Q2 25 | $8.9M | $-36.8M | ||
| Q1 25 | $-11.3M | $105.7M | ||
| Q4 24 | $50.7M | — | ||
| Q3 24 | $22.5M | — | ||
| Q2 24 | $40.4M | $16.7M |
| Q1 26 | — | $7.3M | ||
| Q4 25 | $-5.4M | — | ||
| Q3 25 | $25.8M | — | ||
| Q2 25 | $-11.2M | $-63.2M | ||
| Q1 25 | $-40.2M | $84.4M | ||
| Q4 24 | $21.1M | — | ||
| Q3 24 | $-7.2M | — | ||
| Q2 24 | $10.7M | $6.4M |
| Q1 26 | — | 2.1% | ||
| Q4 25 | -1.2% | — | ||
| Q3 25 | 6.4% | — | ||
| Q2 25 | -2.7% | -18.8% | ||
| Q1 25 | -10.5% | 22.7% | ||
| Q4 24 | 4.8% | — | ||
| Q3 24 | -1.9% | — | ||
| Q2 24 | 2.6% | 1.8% |
| Q1 26 | — | 6.6% | ||
| Q4 25 | 4.0% | — | ||
| Q3 25 | 3.8% | — | ||
| Q2 25 | 4.8% | 7.9% | ||
| Q1 25 | 7.6% | 5.7% | ||
| Q4 24 | 6.7% | — | ||
| Q3 24 | 7.8% | — | ||
| Q2 24 | 7.1% | 2.8% |
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | 3.14× | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | 0.67× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
IART
| Neurosurgery | $226.2M | 52% |
| Asia Pacific | $53.7M | 12% |
| Instruments | $52.3M | 12% |
| ENT | $44.8M | 10% |
| Other | $38.9M | 9% |
| Rest Of The World | $19.0M | 4% |
JACK
| Restaurant Sales | $131.9M | 38% |
| Franchise | $97.4M | 28% |
| Royaltyand Other | $58.9M | 17% |
| Advertising | $56.6M | 16% |
| Technology Service | $4.7M | 1% |
| Franchise Fees | $1.7M | 0% |
